| Home > In process > Anti-CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked? |
| Journal Article | DZNE-2026-00902 |
; ; ; ; ; ; ; ; ;
2026
Wiley
Chichester [u.a.]
This record in other databases:
Please use a persistent id in citations: doi:10.1002/acn3.70414
Abstract: Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti-diacylglycerol lipase alpha (DAGLA) antibody-mediated autoimmune encephalitis, achieving partial clinical remission. We now provide extended follow-up demonstrating a stable, relapse-free clinical course and persistent suppression of autoantibodies. However, the patient exhibited progressive neurodegeneration despite sustained control of B cell-mediated inflammation. This dissociation between immune quiescence and structural decline highlights that CAR T cell therapy, while highly effective in extinguishing inflammation, may not be sufficient to prevent or reverse ongoing neuronal damage in disorders characterized by both inflammation and neurodegeneration.
Keyword(s): Humans (MeSH) ; Encephalitis: immunology (MeSH) ; Encephalitis: therapy (MeSH) ; Hashimoto Disease: therapy (MeSH) ; Hashimoto Disease: immunology (MeSH) ; Antigens, CD19: immunology (MeSH) ; Immunotherapy, Adoptive: methods (MeSH) ; T-Lymphocytes (MeSH) ; Inflammation: immunology (MeSH) ; Inflammation: therapy (MeSH) ; Neurodegenerative Diseases: immunology (MeSH) ; Neurodegenerative Diseases: therapy (MeSH) ; Female (MeSH) ; CAR T cells ; autoimmune encephalitis ; neurodegeneration ; Antigens, CD19
|
The record appears in these collections: |